Q2 EPS Forecast for United Therapeutics Decreased by Analyst

Key Points

• Analysts at **Leerink Partners** have reduced their Q2 2025 earnings per share (EPS) forecast for **United Therapeutics** from **$8.08** to **$7.25**.
• Despite a recent quarterly earnings report showing a beat of $0.34 over estimates, the company's stock has seen price target reductions from various financial institutions.
• United Therapeutics' stock closed down **0.6%** at **$304.50**, with a **market cap of $13.74 billion** and recent insider trading activity indicating a decrease in ownership by company directors.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for United Therapeutics in a note issued to investors on Wednesday, July 23rd. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $7.25 per share for the quarter, down from their prior estimate of $8.08. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q3 2025 earnings at $7.31 EPS, Q4 2025 earnings at $6.97 EPS, FY2025 earnings at $28.16 EPS, FY2026 earnings at $29.26 EPS, FY2027 earnings at $28.69 EPS and FY2028 earnings at $30.05 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.17 EPS.

UTHR has been the topic of a number of other reports. Bank of America dropped their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley decreased their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Stock Down 0.6%

UTHR stock traded down $1.91 during trading on Friday, hitting $304.50. The company had a trading volume of 310,921 shares, compared to its average volume of 372,488. The firm has a market cap of $13.74 billion, a PE ratio of 12.15, a price-to-earnings-growth ratio of 6.68 and a beta of 0.53. The firm has a 50-day moving average price of $300.01 and a 200-day moving average price of $316.20. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in UTHR. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the 2nd quarter worth $29,000. SVB Wealth LLC bought a new position in shares of United Therapeutics during the first quarter worth about $32,000. Dunhill Financial LLC raised its holdings in United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new position in United Therapeutics during the 1st quarter worth approximately $49,000. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,681 shares of company stock valued at $24,628,589. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.